Ipsen S.A. (FRA:I7G)

Market Cap	11.30B +15.6%
Revenue (ttm)	3.76B +11.5%
Net Income	447.90M -32.4%
EPS	5.37 -32.3%
Shares Out	n/a
PE Ratio	25.22
Forward PE	11.56
Dividend	1.40 (1.04%)
Ex-Dividend Date	Jun 4, 2025

Volume	n/a
Average Volume	1
Open	137.10
Previous Close	138.20
Day's Range	137.10 - 137.10
52-Week Range	90.20 - 139.00
Beta	n/a
RSI	66.42
Earnings Date	Feb 12, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,358
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I7G

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.